MAGEA1 and melanoma: Using the melanoma cell line MZ2-MEL and autologous CTL clones cytolytic to this line, MAGE-1 (subsequently re-named MAGE-A1/melanoma antigen A1) was identified as the target antigen for one of the CTL clones, representing the first immunogenic tumor antigen shown to elicit autologous CTL responses in a cancer patient [1].